#United States #Los Angeles #Securities Fraud #SBS Law #Tenax Therapeutics

SBS Law Investigates Tenax Therapeutics for Possible Fraud

Overview of the Investigation

On November 9, 2026, Schall, Brown & Schwartz LLP (commonly referred to as SBS Law), a prominent litigation firm focused on shareholder rights, announced its investigation into Tenax Therapeutics, Inc. This inquiry is aimed at evaluating claims of potential violations of securities laws, particularly concerning the dissemination of misleading information to investors.

The firm is particularly concerned about information surrounding Tenax's clinical trial results. Recent disclosures revealed that Tenax's Phase 3 LEVEL trial, which evaluated its product TNX-103, did not succeed in meeting its critical primary and secondary endpoints. Following this setback, Tenax’s stock suffered a staggering decline, plummeting nearly 90% — a significant loss for its investors.

The Impact on Investors

The fall in stock value not only impacted individual investors but also raised alarms about possible failings in how Tenax communicated its trial results and operational realities. Investors who experienced losses during this period may have grounds for legal action, particularly if it is determined that Tenax issued statements that were inaccurate or deliberately withheld important information.

SBS Law encourages affected shareholders to explore their legal rights and consider joining the investigation aimed at pursuing potential claims against Tenax Therapeutics. Investors interested in discussing their situation can reach out directly to Brian Schall or David Schwartz of SBS Law at their Los Angeles office.

Why SBS Law?

Schall, Brown & Schwartz LLP has built a reputation for aggressively representing investors' rights and handling complex securities litigation. The firm’s expertise centers on class action lawsuits and shareholder representation, which positions them well for advocating on behalf of those negatively impacted by corporate malfeasance. The partners at SBS Law have a wealth of experience in navigating the intricacies of securities regulations, making them an apt choice for disgruntled shareholders affected by Tenax’s recent announcement.

With this investigation, SBS Law aims to unravel the circumstances that led to the drastic share price decline, shedding light on any possible misconduct or failure to comply with securities laws. The investigation is part of a broader effort by SBS to safeguard investors’ interests.

Participation Details

Shareholders who believe they were adversely affected are urged to participate in this investigation. SBS Law promises to handle inquiries confidentially and without obligation. For those wanting to learn more, they can visit the SBS Law website or contact the office via phone or email. Participation in such investigations has proven fruitful for many shareholders in the past, providing avenues for potential recovery of losses.

Conclusion

The unfolding situation at Tenax Therapeutics highlights the importance of corporate transparency and shareholder rights. As the investigation by SBS Law progresses, it could lead to significant developments for investors impacted by the company's recent trial results and subsequent stock price volatility. Stakeholders are encouraged to stay informed and proactive regarding their investments and rights amidst these developments.